Figure 1.

Endometria of women exposed to ulipristal acetate contraceptive vaginal ring (UPA-CVR) display progesterone receptor modulator (PRM)-associated endometrial changes (PAECs). Hematoxylin and eosin staining of endometrial sections obtained from normal mid-secretory phase endometrium (panel A), UPA-CVR releasing 2.5 mg UPA daily for 2 consecutive 12-week treatment periods (panel B), and posttreatment recovery period in the luteal phase (panel C). Note cystic dilatation, mildly disordered architecture, and nonphysiological secretory appearances in the endometria of women with UPA-CVR. These endometrial samples are part of the large clinical trial. Representative images are shown.